Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAZTIA XT vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary arteries and peripheral arterioles, and reduction of myocardial contractility and heart rate.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Hypertension (FDA-approved),Chronic stable angina (FDA-approved),Variant angina (FDA-approved),Atrial fibrillation or atrial flutter (rate control, off-label),Supraventricular tachycardia (off-label)
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Oral, 120 mg or 180 mg once daily. For hypertension, initiate at 120 mg once daily; for angina, initiate at 180 mg once daily. Maximum dose: 360 mg once daily.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
3-5 hours (immediate-release) for diltiazem; after TAZTIA XT extended-release, effective half-life is approximately 7-9 hours due to prolonged absorption. Clinical context: steady state achieved in 3-5 days.
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Hepatic via CYP3A4; active metabolite (desacetyldiltiazem).
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Renal (approximately 60% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion), biliary/fecal (approximately 30-35%)
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
70-80% primarily to albumin; also to alpha-1-acid glycoprotein
92-98% bound to plasma proteins (primarily albumin)
3.1-5.3 L/kg (central compartment); large Vd indicates extensive tissue distribution, consistent with high lipophilicity and cardiac/vascular tissue binding.
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral (extended-release): approximately 35-60% due to extensive first-pass hepatic metabolism (cytochrome P450 3A4) with significant interindividual variability. Food may increase bioavailability by up to 20%.
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
No specific dose adjustment recommended for mild to moderate renal impairment. Use caution in severe renal impairment (Cr Cl <30 m L/min); consider starting at lower dose and titrate slowly.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Child-Pugh Class A or B: No specific adjustment, but use caution. Child-Pugh Class C: Contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Safety and efficacy not established; no pediatric dosing guidelines available.
Not recommended for use in pediatric patients; safety and efficacy not established.
Start at lower end of dosing range (120 mg once daily) due to increased systemic exposure; titrate slowly based on response and tolerability.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
No FDA boxed warning specific to TAZTIA XT; however, the drug class (calcium channel blockers) may have warnings for increased risk of cardiovascular events in certain populations.
No FDA black box warning.
Heart failure: May worsen symptoms due to negative inotropic effects.,Bradycardia and heart block: Risk especially in elderly or with other AV nodal blockers.,Hypotension: Especially with rapid dose escalation.,Abrupt withdrawal: May cause rebound angina or hypertension.,Hepatic impairment: Reduced metabolism may require dose adjustment.,Concomitant use with beta-blockers: Increased risk of bradycardia and heart block.
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Sick sinus syndrome (except with functioning pacemaker),Second- or third-degree AV block (except with pacemaker),Hypotension (systolic <90 mm Hg),Acute myocardial infarction or pulmonary congestion,Known hypersensitivity to diltiazem,Concurrent use with ivabradine
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase diltiazem plasma concentrations, elevating risk of bradycardia and hypotension. No other significant food interactions. Administer with or without food.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
TAZTIA XT (diltiazem) is classified as FDA Pregnancy Category C. In first trimester, animal studies have shown embryofetal toxicity (skeletal abnormalities, fetal mortality) at doses ≥5 times maximum human dose. No adequate human studies in pregnant women; potential risk cannot be ruled out. In second and third trimesters, use may cause uteroplacental hypoperfusion due to maternal hypotension, potentially leading to fetal hypoxia and growth restriction. Case reports associate with preterm labor and low birth weight. Avoid use during pregnancy unless benefit outweighs risk.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
Diltiazem is excreted into breast milk at low concentrations. A study reported milk-to-plasma (M/P) ratio of approximately 0.8-1.0. Estimated infant dose is <1% of maternal weight-adjusted dose, considered clinically insignificant. However, due to potential for adverse effects (hypotension, bradycardia) in neonates, caution advised. American Academy of Pediatrics considers diltiazem compatible with breastfeeding. Monitor infant for signs of bradycardia or hypotension.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
No standard dosing adjustments established for pregnancy. However, pregnancy-induced physiological changes (increased plasma volume, renal clearance, and hepatic metabolism) may reduce diltiazem plasma concentrations. Monitor therapeutic effect and consider dose titration based on blood pressure response and heart rate. Limited data suggest that higher doses may be required. Adjust dose cautiously to avoid maternal hypotension, which could compromise uteroplacental perfusion.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
TAZTIA XT is a once-daily extended-release formulation of diltiazem (240 mg, 300 mg, 360 mg). Use for hypertension or chronic stable angina. Doses >360 mg are not recommended. Do not crush or chew; the matrix delivery system can cause bezoars. Avoid use in sick sinus syndrome without a pacemaker, second- or third-degree AV block, or hypotension (SBP <90 mm Hg). Monitor for bradycardia and peripheral edema. Abrupt withdrawal may exacerbate angina. Contraindicated with IV beta-blockers or in patients with atrial fibrillation/flutter with accessory bypass tract (e.g., WPW).
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Take TAZTIA XT once daily at approximately the same time every day, with or without food.,Swallow the capsule whole; do not crush, chew, or open it. The empty shell may appear in stool.,Avoid grapefruit and grapefruit juice as it can increase diltiazem levels and risk of side effects.,Do not suddenly stop taking this medication without consulting your doctor, as chest pain or heart attack may worsen.,Report symptoms like slow heartbeat, dizziness, fainting, or swelling of the ankles/feet.,Limit alcohol intake as it can increase dizziness and lower blood pressure.,Warn about interactions with beta-blockers, digoxin, statins, and CYP3A4 inhibitors/inducers.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAZTIA XT vs AFEDITAB CR, answered by our medical review team.
TAZTIA XT is a Calcium Channel Blocker that works by Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary arteries and peripheral arterioles, and reduction of myocardial contractility and heart rate.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAZTIA XT and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAZTIA XT is: Oral, 120 mg or 180 mg once daily. For hypertension, initiate at 120 mg once daily; for angina, initiate at 180 mg once daily. Maximum dose: 360 mg once daily.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TAZTIA XT and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TAZTIA XT is classified as Category C. TAZTIA XT (diltiazem) is classified as FDA Pregnancy Category C. In first trimester, animal studies have shown embryofetal toxicity (skeletal abnormalities, fetal mortality) at dos. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.